BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
See today's BioWorld
Home
» Amgen Previews 2011 Sales of Neulasta, Xgeva, Prolia
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Amgen Previews 2011 Sales of Neulasta, Xgeva, Prolia
Jan. 10, 2012
By
Karen Carey
No Comments
Providing an early sales glance, Amgen Inc. CEO-elect Bob Bradway reported Monday that the company's denosumab franchise, consisting of Xgeva and Prolia, generated more than $500 million in revenue in 2011, their first full year on the market.
BioWorld